In total, there were 76 patients in the efficacy analysis set (i.e., these patients had measurable disease at baseline by IRC per RECIST v1.1 and ≥ 1 evaluable post-baseline tumor assessment [TNBC cohort, n = 55; HR+/HER2− cohort, n = 21]). The gene discussed is ERBB2; the disease is neoplasm.